[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO5631458A2 - Vehiculos inyectables solidos de acido hialurico para administracion de proteinas osteogenicas - Google Patents

Vehiculos inyectables solidos de acido hialurico para administracion de proteinas osteogenicas

Info

Publication number
CO5631458A2
CO5631458A2 CO04122903A CO04122903A CO5631458A2 CO 5631458 A2 CO5631458 A2 CO 5631458A2 CO 04122903 A CO04122903 A CO 04122903A CO 04122903 A CO04122903 A CO 04122903A CO 5631458 A2 CO5631458 A2 CO 5631458A2
Authority
CO
Colombia
Prior art keywords
bmp
composition
administration
osteogenic protein
hialuric
Prior art date
Application number
CO04122903A
Other languages
English (en)
Inventor
Rebecca H Li
Hyun D Kim
Original Assignee
Wyeth Corp
Fidia Advanced Biopolymers Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp, Fidia Advanced Biopolymers Srl filed Critical Wyeth Corp
Publication of CO5631458A2 publication Critical patent/CO5631458A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)

Abstract

1.- Una composición para la administración de proteínas osteogénicas que comprende una proteína osteogénica y un éster de ácido hialurónico, estando dicha composición en forma de un bastoncillo cilíndrico apropiada para inyección o implantación en estado sólido en un cuerpo.2.- La composición de la reivindicación 1, donde la proteína osteogénica se selecciona entre el grupo compuesto por los miembros de la familia de las proteínas morfogénicas óseas (BMP).3.- La composición de la reivindicación 2, donde la proteína osteogénica se selecciona entre el grupo compuesto por BMP-2, BMP-4, BMP-5, BMP-6, BMP-7, BMP-10, BMP-12 y BMP-13.4.- La composición de la reivindicación 2, donde la proteína osteogénica es BMP-2 o BMP-6.5.- La composición de la reivindicación 1, que también comprende un inhibidor de la resorción ósea.6.- La composición de la reivindicación 5, donde el inhibidor de la resorción ósea es un bisfosfonato.7.- La composición de la reivindicación 6, donde el bisfosfonato se selecciona entre el grupo formado por alendronato, cimadronato, clodronato, EB-1053, etidronatos, ibandronato, neridronato, olpadronato, pamidronato, risedronato, tiludronato, YH 529, zolendronato, y sales farmacéuticamente aceptables, ésteres, ácidos, y mezclas de los mismos.
CO04122903A 2002-05-17 2004-12-07 Vehiculos inyectables solidos de acido hialurico para administracion de proteinas osteogenicas CO5631458A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38159002P 2002-05-17 2002-05-17

Publications (1)

Publication Number Publication Date
CO5631458A2 true CO5631458A2 (es) 2006-04-28

Family

ID=29584319

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04122903A CO5631458A2 (es) 2002-05-17 2004-12-07 Vehiculos inyectables solidos de acido hialurico para administracion de proteinas osteogenicas

Country Status (17)

Country Link
US (2) US20050287135A1 (es)
EP (1) EP1519744A4 (es)
JP (1) JP4879482B2 (es)
CN (1) CN1665525A (es)
AR (1) AR039548A1 (es)
AU (1) AU2003228958C1 (es)
BR (1) BR0310087A (es)
CA (1) CA2486113A1 (es)
CO (1) CO5631458A2 (es)
EA (1) EA008354B1 (es)
IL (1) IL165077A0 (es)
MX (1) MXPA04011337A (es)
NO (1) NO20045507L (es)
NZ (1) NZ536478A (es)
TW (2) TW200638946A (es)
WO (1) WO2003099992A2 (es)
ZA (1) ZA200409096B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0608053B1 (en) * 1993-01-11 1999-12-01 Canon Kabushiki Kaisha Colour display system
ES2225241T3 (es) * 1999-10-15 2005-03-16 Genetics Institute, Llc Formulaciones de acido hialuronico para suministrar proteinas osteogenicas.
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
DE602004005477T2 (de) 2003-09-12 2007-12-13 Wyeth Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen
CZ13928U1 (cs) * 2003-10-08 2004-01-20 Cpn Spol. S R.O. Dietetický přípravek pro prevenci a léčbu osteoporózy
AR046773A1 (es) * 2003-12-23 2005-12-21 Novartis Ag Formulaciones farmaceuticas de bisfosfonatos
PT1713489E (pt) * 2004-08-23 2011-03-03 Teva Pharma Forma cristalina de ibandronato de sódio e processos para a sua preparação
ITMI20052515A1 (it) * 2005-12-29 2007-06-30 Abiogen Pharma Spa Formulazione farmaceutica per il trattamento della osteoartrite
CA2616421A1 (en) * 2006-05-23 2007-11-29 Mathys Ag Bettlach Solid precursor for the preparation of a pasty bone replacement material by admixture of a liquid.
AR063121A1 (es) * 2006-10-05 2008-12-30 Novartis Ag Composicion farmaceutica
CA2986192C (en) 2007-07-10 2022-06-14 Peter Forsell Hip joint device and method
FR2919188B1 (fr) * 2007-07-27 2010-02-26 Proteins & Peptides Man Complexes entre un polymere amphiphile et une proteine osteogenique appartenant a la famille des bmps
WO2009127939A1 (fr) * 2008-04-14 2009-10-22 Adocia Composition osteogenique comprenant un facteur de croissance un sel soluble de cation et un support organique
BRPI0906553A2 (pt) * 2008-04-14 2015-07-07 Adocia ''implante aberto constituído por uma composição osteogênica e método de preparação do implante''
US8759322B2 (en) 2008-11-05 2014-06-24 National University Corporation Tokyo Medical And Dental University Hyaluronic acid derivative and pharmaceutical composition thereof
US8524662B2 (en) 2010-12-28 2013-09-03 Depuy Mitek, Llc Compositions and methods for treating joints
US8455436B2 (en) 2010-12-28 2013-06-04 Depuy Mitek, Llc Compositions and methods for treating joints
US8398611B2 (en) 2010-12-28 2013-03-19 Depuy Mitek, Inc. Compositions and methods for treating joints
US8623839B2 (en) 2011-06-30 2014-01-07 Depuy Mitek, Llc Compositions and methods for stabilized polysaccharide formulations
KR102016745B1 (ko) * 2013-02-01 2019-09-02 아이진 주식회사 Ｂｍｐ―７ 및 부형제를 포함하는 흉터 형성의 감소 또는 억제용 조성물
US9682099B2 (en) 2015-01-20 2017-06-20 DePuy Synthes Products, Inc. Compositions and methods for treating joints
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
SG11202102481QA (en) * 2018-09-14 2021-04-29 Orthocell Ltd Artificial periosteum

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2465257A (en) * 1945-09-12 1949-03-22 Universal Moulded Products Cor Laminated tubular article
CH563767A5 (es) * 1973-01-30 1975-07-15 Pheulpin Jean
DE2657370C2 (de) * 1976-12-17 1982-11-11 Hans Dr.med. Dr.med.dent. 8000 München Scheicher Mittel zum Bedecken und/oder Ausfüllen von Knochendefekten
DE2732848A1 (de) * 1977-07-18 1979-02-08 Schering Ag Diurethane, herbizide mittel enthaltend diese verbindungen sowie verfahren zu ihrer herstellung
US4455256A (en) * 1981-05-05 1984-06-19 The Regents Of The University Of California Bone morphogenetic protein
US4727028A (en) * 1981-06-22 1988-02-23 Eli Lilly And Company Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
IL68218A (en) * 1983-03-23 1985-12-31 Univ Ramot Compositions for cartilage repair comprising embryonal chondrocytes
US4434094A (en) * 1983-04-12 1984-02-28 Collagen Corporation Partially purified osteogenic factor and process for preparing same from demineralized bone
US4795804A (en) * 1983-08-16 1989-01-03 The Regents Of The University Of California Bone morphogenetic agents
US4923805A (en) * 1983-11-02 1990-05-08 Integrated Genetics, Inc. Fsh
GB8334498D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Compounds
US4804744A (en) * 1984-01-04 1989-02-14 International Genetic Engineering, Inc. Osteogenic factors
US4662884A (en) * 1984-04-25 1987-05-05 University Of Utah Research Foundation Prostheses and methods for promoting nerve regeneration
US4596574A (en) * 1984-05-14 1986-06-24 The Regents Of The University Of California Biodegradable porous ceramic delivery system for bone morphogenetic protein
CA1341617C (en) * 1984-06-08 2011-06-28 Henry George Burger Inhibin isolated from ovarian follicular fluid
US4843063A (en) * 1984-07-16 1989-06-27 Collagen Corporation Polypeptide cartilage-inducing factors found in bone
EP0169016B2 (en) * 1984-07-16 2004-04-28 Celtrix Pharmaceuticals, Inc. Polypeptide cartilage-inducing factors found in bone
US5187263A (en) * 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
US4563350A (en) * 1984-10-24 1986-01-07 Collagen Corporation Inductive collagen based bone repair preparations
US4828990A (en) * 1984-12-27 1989-05-09 Naoki Higashi Method for purifying an interferon
US4681763A (en) * 1985-06-11 1987-07-21 University Of Medicine And Dentistry Of New Jersey Composition for stimulating bone growth
US4851521A (en) 1985-07-08 1989-07-25 Fidia, S.P.A. Esters of hyaluronic acid
US5215893A (en) * 1985-10-03 1993-06-01 Genentech, Inc. Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US4798885A (en) * 1986-02-07 1989-01-17 Genentech, Inc. Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain
US5089396A (en) * 1985-10-03 1992-02-18 Genentech, Inc. Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid
US5133755A (en) * 1986-01-28 1992-07-28 Thm Biomedical, Inc. Method and apparatus for diodegradable, osteogenic, bone graft substitute device
US4737578A (en) * 1986-02-10 1988-04-12 The Salk Institute For Biological Studies Human inhibin
US4758233A (en) * 1986-04-22 1988-07-19 N.J. Phillips TPY. Limited Cream applicator
NL8601328A (nl) * 1986-05-23 1987-12-16 Langen Research Inrichting voor het met een massa, in het bijzonder pasteuze massa, injekteren van vlees.
US5106748A (en) * 1986-07-01 1992-04-21 Genetics Institute, Inc. Dna sequences encoding 5 proteins
US5543394A (en) * 1986-07-01 1996-08-06 Genetics Institute, Inc. Bone morphogenetic protein 5(BMP-5) compositions
US5187076A (en) * 1986-07-01 1993-02-16 Genetics Institute, Inc. DNA sequences encoding BMP-6 proteins
US5631142A (en) * 1986-07-01 1997-05-20 Genetics Institute, Inc. Compositions comprising bone morphogenetic protein-2 (BMP-2)
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US5108922A (en) * 1986-07-01 1992-04-28 Genetics Institute, Inc. DNA sequences encoding BMP-1 products
US6432919B1 (en) * 1986-07-01 2002-08-13 Genetics Institute, Inc. Bone morphogenetic protein-3 and compositions
US5459047A (en) * 1986-07-01 1995-10-17 Genetics Institute, Inc. BMP-6 proteins
US5013649A (en) * 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5019087A (en) * 1986-10-06 1991-05-28 American Biomaterials Corporation Nerve regeneration conduit
IT1198449B (it) 1986-10-13 1988-12-21 F I D I Farmaceutici Italiani Esteri di alcoli polivalenti di acido ialuronico
US5124316A (en) * 1986-11-14 1992-06-23 President And Fellows Of Harvard College Method for periodontal regeneration
US5202120A (en) * 1987-09-11 1993-04-13 Case Western Reserve University Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes
US5258494A (en) * 1988-04-08 1993-11-02 Stryker Corporation Osteogenic proteins
US5108753A (en) * 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
US5011691A (en) * 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
US5284756A (en) * 1988-10-11 1994-02-08 Lynn Grinna Heterodimeric osteogenic factor
US5106626A (en) * 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5011486A (en) * 1988-11-18 1991-04-30 Brown University Research Foundation Composite nerve guidance channels
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US4920962A (en) * 1988-11-23 1990-05-01 Claude Proulx Splint-like element for use in end-to-end nerve suture
US5217867A (en) * 1988-11-30 1993-06-08 The Salk Institute For Biological Studies Receptors: their identification, characterization, preparation and use
US5202421A (en) * 1988-12-27 1993-04-13 Mochida Pharmaceutical Co., Ltd. Anticoagulant substance obtained from urine and process for the preparation thereof
US5026381A (en) * 1989-04-20 1991-06-25 Colla-Tec, Incorporated Multi-layered, semi-permeable conduit for nerve regeneration comprised of type 1 collagen, its method of manufacture and a method of nerve regeneration using said conduit
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
AU5958090A (en) * 1989-06-29 1991-01-17 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Method for protecting bone marrow against chemotherapeutic drugs and radiation therapy using transforming growth factor beta 1
US5324519A (en) * 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5422340A (en) * 1989-09-01 1995-06-06 Ammann; Arthur J. TGF-βformulation for inducing bone growth
US5236456A (en) * 1989-11-09 1993-08-17 Osteotech, Inc. Osteogenic composition and implant containing same
US5290271A (en) * 1990-05-14 1994-03-01 Jernberg Gary R Surgical implant and method for controlled release of chemotherapeutic agents
WO1991017777A2 (en) 1990-05-22 1991-11-28 University Of Florida Injectable bioactive glass compositions and methods for tissue reconstruction
US5218090A (en) * 1990-06-12 1993-06-08 Warner-Lambert Company EGF receptor truncates
US5206028A (en) * 1991-02-11 1993-04-27 Li Shu Tung Dense collagen membrane matrices for medical uses
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
US5318898A (en) * 1991-04-02 1994-06-07 Genetics Institute, Inc. Production of recombinant bone-inducing proteins
US5118667A (en) * 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
IT1247472B (it) * 1991-05-31 1994-12-17 Fidia Spa Processo per la preparazione di microsfere contenenti componenti biologicamente attivi.
US5216126A (en) * 1991-06-19 1993-06-01 Genentech, Inc. Receptor polypeptides and their production and uses
US6287816B1 (en) * 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US5356629A (en) 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
US5306307A (en) * 1991-07-22 1994-04-26 Calcitek, Inc. Spinal disk implant
JP3504263B2 (ja) * 1991-11-04 2004-03-08 ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー 組み換え型骨形態形成蛋白ヘテロダイマー、組成物および使用法
SE469653B (sv) 1992-01-13 1993-08-16 Lucocer Ab Poroest implantat
AU666712B2 (en) 1992-02-28 1996-02-22 Cohesion Technologies, Inc. Injectable ceramic compositions and methods for their preparation and use
IT1259090B (it) 1992-04-17 1996-03-11 Fidia Spa Biomaterialli per protesi d'osso
IT1259100B (it) 1992-05-20 1996-03-11 Lanfranco Callegaro Uso di idrogeli per il bloccaggio di sistemi protesici
CZ283073B6 (cs) 1992-11-03 1997-12-17 Chemickotechnologická Fakulta Stu Bioaktivní materiál a způsob jeho přípravy
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5420243A (en) * 1993-01-26 1995-05-30 Celtrix Pharmaceuticals, Inc. Biologically active TGF-β2 peptides
GB9308060D0 (en) * 1993-04-19 1993-06-02 Cancer Res Campaign Tech Stem cell inhibitor
US5637480A (en) * 1993-05-12 1997-06-10 Genetics Institute, Inc. DNA molecules encoding bone morphogenetic protein-10
EP2272959A1 (en) * 1993-05-12 2011-01-12 Genetics Institute, LLC BMP-11 compositions
DK0716610T3 (da) * 1993-08-26 2006-09-04 Genetics Inst Llc Humane knogle-morfogenetiske proteiner til anvendelse ved neural regenerering
DK0733109T3 (da) * 1993-12-07 2006-07-03 Genetics Inst Llc BMP-12, BMP-13 og seneinducerende præparater dermed
US5399677A (en) * 1993-12-07 1995-03-21 Genetics Institute, Inc. Mutants of bone morphogenetic proteins
US6027919A (en) * 1993-12-07 2000-02-22 Genetics Institute, Inc. BMP-12 and BMP-13 proteins and DNA encoding them
ITPD940054A1 (it) * 1994-03-23 1995-09-23 Fidia Advanced Biopolymers Srl Polisaccaridi solfatati
US5520923A (en) * 1994-09-19 1996-05-28 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5635372A (en) * 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
EP0831884B1 (en) * 1995-06-05 2003-07-30 Genetics Institute, LLC Use of bone morphogenic proteins for healing and repair of connective tissue attachment
US5716413A (en) * 1995-10-11 1998-02-10 Osteobiologics, Inc. Moldable, hand-shapable biodegradable implant material
US5752974A (en) * 1995-12-18 1998-05-19 Collagen Corporation Injectable or implantable biomaterials for filling or blocking lumens and voids of the body
IT1282219B1 (it) * 1995-12-20 1998-03-16 Fidia Advanced Biopolymers Srl Processo chimico fisico combinato per la preparazione di frazioni di acido ialuronico a basso peso molecolare caratterizzate da bassa
AU729086C (en) 1996-03-05 2006-12-14 Depuy Acromed, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
WO1997032591A1 (en) 1996-03-05 1997-09-12 Orquest, Inc. Method of promoting bone growth with hyaluronic acid and growth factors
WO1997045532A1 (en) 1996-05-28 1997-12-04 Brown University Research Foundation Hyaluronan based biodegradable scaffolds for tissue repair
IT1288290B1 (it) 1996-06-21 1998-09-11 Fidia Spa In Amministrazione S Acido ialuronico autoreticolato e relative composizioni farmaceutiche per il trattamento delle artropatie
EP1350525A3 (en) 1997-02-07 2003-12-10 Stryker Corporation Matrix-free osteogenic devices, implants and methods thereof
US6034062A (en) * 1997-03-13 2000-03-07 Genetics Institute, Inc. Bone morphogenetic protein (BMP)-9 compositions and their uses
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
IT1296689B1 (it) 1997-11-06 1999-07-14 Fidia Advanced Biopolymers Srl Derivati esterei dell'acido ialuronico aventi proprieta viscoelastiche e loro uso in campo biomedico-sanitario
US6630457B1 (en) * 1998-09-18 2003-10-07 Orthogene Llc Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same
IT1302534B1 (it) 1998-12-21 2000-09-05 Fidia Advanced Biopolymers Srl Composizioni iniettabili, biocompatibili e biodegradabili comprendentialmeno un derivato dell'acido ialuronico, cellule condrogeniche, per
JP4211108B2 (ja) * 1999-01-13 2009-01-21 生化学工業株式会社 高粘弾性物質の注入器具
ES2225241T3 (es) * 1999-10-15 2005-03-16 Genetics Institute, Llc Formulaciones de acido hialuronico para suministrar proteinas osteogenicas.

Also Published As

Publication number Publication date
EA008354B1 (ru) 2007-04-27
AR039548A1 (es) 2005-02-23
CN1665525A (zh) 2005-09-07
AU2003228958C1 (en) 2009-01-08
NZ536478A (en) 2008-02-29
EP1519744A2 (en) 2005-04-06
TW200307559A (en) 2003-12-16
US20090181058A1 (en) 2009-07-16
EA200401502A1 (ru) 2005-08-25
JP2005532335A (ja) 2005-10-27
MXPA04011337A (es) 2005-07-01
TWI282283B (en) 2007-06-11
IL165077A0 (en) 2005-12-18
NO20045507L (no) 2004-12-16
EP1519744A4 (en) 2007-10-03
BR0310087A (pt) 2005-08-16
CA2486113A1 (en) 2003-12-04
WO2003099992A3 (en) 2004-05-27
AU2003228958B2 (en) 2008-05-01
TW200638946A (en) 2006-11-16
AU2003228958A2 (en) 2003-12-12
US20050287135A1 (en) 2005-12-29
JP4879482B2 (ja) 2012-02-22
ZA200409096B (en) 2006-06-28
AU2003228958A1 (en) 2003-12-12
US7875590B2 (en) 2011-01-25
WO2003099992A2 (en) 2003-12-04

Similar Documents

Publication Publication Date Title
CO5631458A2 (es) Vehiculos inyectables solidos de acido hialurico para administracion de proteinas osteogenicas
AR045935A1 (es) Barras solidas y pastas de fosfato de calcio inyectables para el suministro de proteinas osteogenicas
NL300223I1 (nl) Werkwijze voor het inhibiteren van botresorptie.
HRP20020594B1 (en) Pharmaceutical parenteral composition containing a biphosphonate
JP2016527006A5 (es)
WO2008067088A1 (en) Implant designs and methods of improving cartilage repair
DK1296689T3 (da) Fremgangsmåde til indgivelse af bisphosphonater
NZ545804A (en) Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-or-vitamin D derivatives and a bisphosphonate
JP2005530819A5 (es)
KR970705400A (ko) 골 활성 포스포네이트 및 부갑상선 호르몬을 사용한 골다공증의 치료방법(methods for the treatment of osteoporosis using bone active phosphonates and parathyroid hormone)
RU2004122433A (ru) Способ лечения костных нарушений
CO5300464A1 (es) Metodo para regular la angiogenesis utilizando proteina ryk
YU1800A (sh) Upotreba bisfosfonata za proizvodnju leka za inhibiranje resorpcije kostiju

Legal Events

Date Code Title Description
FC Application refused